Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. director F. Thomas Kirk reported two open-market purchases of common stock. On May 15, 2026, he bought 31,605 shares at a weighted average price of $0.9096 per share, in multiple lots priced between $0.815 and $0.91.
On May 18, 2026, he bought an additional 43,401 shares at a weighted average price of $0.91 per share, with individual trades between $0.9041 and $0.91. After these purchases, he directly owns 628,863 common shares.
Myomo, Inc. received an amended Schedule 13D from Horton Capital entities and Joseph M. Manko Jr., disclosing beneficial ownership of 2,309,775 common shares, or about 6.0% of the company based on 38,638,653 shares outstanding as of May 1, 2026.
The shares, held through Horton Capital Partners Fund, were bought in open-market transactions for an aggregate purchase price of about $3.6 million. Manko was appointed to Myomo’s board of directors effective May 9, 2026, to serve until the 2027 annual meeting.
Horton Capital submitted a shareholder proposal for the 2026 proxy asking Myomo to declassify its board so all directors stand for annual election. The filing notes the group may continue to engage with management and other shareholders and could increase or decrease its stake over time.
MYOMO, INC. director Joseph M. Manko Jr., through Horton Capital Partners Fund, LP, reported net open-market purchases of 201,197 MYO shares. The fund bought 170,830 shares at an average price of $0.8602 per share on May 14, 2026, and 30,367 shares at $0.8878 per share on May 15, 2026. Following these indirect transactions, the fund’s reported MYO holdings rose to 2,309,775 shares.
MYOMO, INC. director Joseph M. Manko Jr. filed an initial Form 3 reporting his beneficial ownership in the company. The filing shows indirect ownership of 2,108,578 MYO shares, held through Horton Capital Partners Fund, LP, reflecting his existing stake rather than a new transaction.
MYOMO, INC. Chief Commercial Officer Micah Mitchell reported an open-market sale of 90,231 shares of common stock on May 14. The weighted average sale price was $0.861 per share, with individual trades executed between $0.85 and $0.889 per share. After these transactions, Mitchell directly owns 109,478 shares of Myomo common stock.
MYO filed a Form 144 reporting a proposed sale of 90,231 shares of Common Stock by Morgan Stanley Smith Barney LLC Executive Financial Services. The submission lists multiple tranches of restricted stock dated 06/05/2024, 06/07/2024, 06/28/2024, 03/11/2025, 06/05/2025, and 06/28/2025.
The form provides per‑tranche counts (for example, 24,500 shares on 06/28/2024 and 40,000 shares on 06/28/2025) and names the selling broker. Timing and sale mechanics beyond the listed dates are not detailed in the excerpt.
Myomo, Inc. is asking stockholders at its virtual 2026 annual meeting to elect two Class III directors, approve executive pay on an advisory basis, and ratify CBIZ CPAs P.C. as auditor for 2026. Stockholders are also being asked to approve Amendment No. 3 to the 2018 Stock Option and Incentive Plan, increasing shares available under the plan by 1,833,000 shares, and to approve an amendment to the certificate of incorporation to increase the number of authorized shares of common stock to 100,000,000 shares. The agenda includes an advisory stockholder proposal from Horton Fund to declassify the board, authority to adjourn the meeting if needed, and other routine business items.
Myomo, Inc. appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026. He will serve as a Class I director until the 2027 annual meeting of stockholders, when he will be eligible for election by shareholders.
Manko, age 60, is Senior Principal of Horton Capital Management LLC, a significant Myomo shareholder, and brings more than 25 years of experience across investment banking, private equity, asset management and corporate strategy. With his appointment, Myomo’s Board now has seven directors.
He will receive the same compensation as other non-employee directors beginning after the 2026 annual meeting, currently an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000. He has entered into a standard indemnification agreement with the company, and there are no related-party transactions requiring disclosure.
Myomo, Inc. reported Q1 2026 revenue of $10.1 million, up about 3% from a year earlier, as higher average selling prices and international sales offset softer direct-to-patient volume. Gross margin improved to 68.2% from 67.2%, helped by pricing and lower material costs despite higher clinical expenses.
The company recorded a net loss of $3.0 million, narrowed from $3.5 million, and negative operating cash flow of $2.2 million. Adjusted EBITDA loss improved to $2.3 million from $2.8 million as operating expenses were roughly flat, with lower R&D and G&A partly offset by higher selling, clinical and marketing costs tied to advertising and new clinical sales staff.
Myomo ended the quarter with $15.7 million in cash, cash equivalents and short-term investments and working capital of $16.3 million. Long-term debt totaled $12.6 million under a Avenue term loan facility, whose derivative and warrant features produced a non-cash gain from a lower fair value. Management expects current liquidity to fund operations for at least 12 months while focusing on growing recurring MyoConnect and O&P channel revenues and reducing advertising-driven customer acquisition costs.